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ABSTRACT
Introduction: Topical 5-fluorouracil (5-FU) has
been used to treat actinic keratosis for decades.
It has been an important and effective
treatment which the patient can
self-administer, but is limited by the surface
area of skin to be treated (according to the
manufacturer’s guidelines) of 500 cm2. Other
topical treatments can be painful, or require
hospital/health care professional input. The use
of 5-FU under occlusion (chemowraps) for large
areas of sun-damaged skin on the arms or legs
has been described and is a potentially useful
treatment option. We describe our experiences
with this technique in the Norfolk and Norwich
University Hospital Dermatology Department
(Norwich, UK).
Methods: Five patients were recruited into this
pilot study. Topical 5-FU was applied to
sun-damaged limbs under occlusion, and
reviewed weekly for response, and local or
systemic side effects. Treatment duration was
12–14 weeks. Clinical photography was
undertaken prior to, during, and after
treatment to document response.
Results: We show that there was substantial
clinical improvement in the treated skin in our
patients. Experienced dermatologists reviewed
all the patients, and documented the changes
photographically, and by counting lesions. All
patients were satisfied with their treatment
regimen, and also with the end result;
although two did not complete the treatment
regimen due to complications not directly
attributable to the treatment.
Conclusion: Topical 5-FU under occlusion
(chemowraps) may be a valid treatment option
for large areas of sun-damaged skin with field
cancerization changes, due to low systemic and
local toxicity, and acceptability to patients.
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INTRODUCTION
5-Fluorouracil (5-FU) has been used to treat
actinic or solar keratoses for over 50 years. Its
main mode of action is due to its structure (a
pyrimidine analog) and it binds irreversibly to
thymidylate synthetase. 5-FU in a 5% w/w
formulation (Efudix, Meda Pharmaceuticals
Ltd., Bishop’s Stortford, UK) is a standard
topical treatment in the UK for precancerous
conditions such as Bowen’s disease, actinic
keratosis, or superficial basal cell carcinoma
(SBCC). The efficacy of treatment and
durability of response for actinic keratoses
treatment have recently been demonstrated [1].
Sun-damaged skin may exhibit ‘‘field
cancerization’’, that is, a wide area of skin with
dysplastic epithelium and a high risk of
multiple primary cancers arising separately
from this large background area of abnormal
cells. Treatment of large surface areas is
challenging. Treatments available include:
photodynamic therapy (PDT), which is painful
and expensive, and so is often inappropriate in
an era of National Health Service (NHS)
financial austerity; cryotherapy [2], which
requires skill and is not suitable for large areas
due to pain and risk of ulceration in elderly,
edematous legs with poor peripheral vascular
supply; and CO2 laser resurfacing and chemical
peels, which are not available in most UK NHS
hospitals. Furthermore, other topical
treatments available include: Imiquimod 5%
cream, colchicine, ingenol mebutate, and
diclofenac, although data on their efficacy for
patients with large areas of disease are scanty.
The standard treatment regimen for 5-FU is
for topical application to the lesions and
surrounding area, once or twice a day, for
3–4 weeks. The recommended (according to
the manufacturer’s guidelines) maximum
treated surface area of skin at one time is
500 cm2. Two groups have reported the use of
5-FU topically under occlusion (chemowraps) to
treat diffuse and heavily ultraviolet
(UV)-damaged legs in the elderly population
[3, 4]. In this pilot study, we describe our initial
experiences with five patients treated with 5-FU
chemowraps for diffusely actinic-damaged
limbs.
METHODS
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study. All
patients were seen in the Norfolk and Norwich
University Hospital’s Department of
Dermatology (Norwich, UK).
Patients were informed that topical
treatment with 5-FU in this way is an off-label
treatment. Five unselected patients with diffuse
and heavily UV-damaged limbs consented to
treatment. Clinical photography was used to
document the lesions and extent of disease
prior to, during, and after treatment. Twenty
grams of 5-FU was applied to cover each leg,
with occlusion using zinc oxide and crepe
bandages at each weekly visit. In our patient
with arm lesions, 10 g of 5-FU was applied to
cover each arm, again under occlusion.
Occlusion was maintained for the week, and
patients were reviewed weekly for response,
clinical toxicity, and further treatment
applications. All patients were reviewed by
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experienced dermatologists and a specialist
nurse. Lesions were noted for their position,
and counted, prior to photography. Any lesion
suspicious for squamous cell carcinoma (SCC)
was excised for histopathology.
Patients were questioned informally at the
end of treatment about their satisfaction with
their treatment and the outcomes (formal
patient satisfaction questionnaires not
undertaken).
RESULTS
Table 1 shows details of the five patients
involved in the 5-FU ‘‘chemowrap’’ treatment.
All patients were subjected to weekly reviews
with clinical monitoring throughout. Potential
side effects of toxicity that were monitored for
included neutropenia, mucositis, and diarrhea;
however, no side effects were detected. Table 1
clearly documents our patients’ details on
duration of treatment, treatment breaks,
completion of treatment, toxicity of
treatment, and previous treatments prior to
commencement of chemowraps. Two patients
did not complete the regimen of treatment,
both due to non-treatment-related
complications. See Fig. 1 for photographic
comparisons.
DISCUSSION
We have presented here the results of our
experiences with chemowraps in a small
cohort of patients. The results have been very
encouraging. All patients who completed the
regimen showed objective evidence of
improvement, with a decrease in the numbers
of actinic keratoses or a reduction in the size of
lesions. Close monitoring of patients for
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toxicity did not reveal any adverse events. Two
patients did not complete their treatment, due
to non-treatment-related complications. All
patients reported satisfaction with the
treatment regimen and their outcomes, even if
they did not complete treatment.
Mann et al. [3] described their experiences of
treating three patients (but representative of
over 200 patients) with significant actinic
damage with 5-FU chemowraps. Only two
patients reported hair loss and possible contact
allergy to 5-FU, and there were no serious
adverse events. It was reported that skin
irritation was minimal compared with the
standard regimen of once or twice daily
application of 5-FU. Most patients reported
satisfaction with the treatment, although no
formal survey was undertaken. Tallon and
Turnbull [4] reported excellent response rates
and patient satisfaction in their cohort of five
patients.
Systemic toxicity with 5-FU is a primary
concern. It is known that the rate-limiting
enzyme dihydropyrimidine dehydrogenase
(DPD), which is encoded by the DPYD gene,
deactivates more than 80% of standard oral
doses of 5-FU and its prodrug, capecitabine [5].
True (complete) deficiency of DPD is found in
approximately 5% of the population, and drug
half-life is prolonged, with accumulation of
drug and subsequent toxicity [5]. A further
3–5% of the population have variant
mutations in DPYD, which decrease enzymatic
activity, and are more susceptible to toxicity [6].
Although our patients only received topical
5-FU, we monitored them closely for clinical
signs of systemic toxicity such as neutropenia,
diarrhea, and mucositis. None of our patients
demonstrated any adverse events.
Local experiences with these 5-FU
chemowraps have been positive. There is a
dearth of effective, well-tolerated, and safe
treatment options available for patients with
diffuse actinic damage on their limbs. A recent
randomized-controlled clinical trial
demonstrated superiority of imiquimod 5%
treatment to 5-FU topically (standard regimen)
or cryosurgery [7]. It is interesting to speculate
that treatment under occlusion with topical
5-FU would be more successful than the
standard regimen. Potential advantages of
chemowraps compared to some of the other
topical treatments include the ability to treat
large surface areas and the lack of pain or
discomfort so far.
Our experiences with 5-FU chemowraps
suggest that this off-label treatment modality
is a useful option for patients with large areas of
Fig. 1 Photos of two representative patients who
completed chemowrap treatment. White arrows point to
actinic keratoses or Bowenoid lesions which have evidently
improved after treatment, by resolving completely, or
diminishing in size and thickness
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diffuse actinic damage. There appears to be a
low risk of systemic or local toxicity with this
regimen, but since the majority of patients with
large areas of sun-damaged skin are the elderly,
consideration of co-morbidities or unstable
medical conditions are highly important. The
data suggest that a properly randomized,
blinded, and controlled clinical trial is
required to establish the true efficacy of
chemowraps.
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